株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アルコール性肝炎:パイプライン製品の分析

Alcoholic Hepatitis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 302501
出版日 ページ情報 英文 67 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
アルコール性肝炎:パイプライン製品の分析 Alcoholic Hepatitis - Pipeline Review, H2 2016
出版日: 2016年09月14日 ページ情報: 英文 67 Pages
概要

アルコール性肝炎は、肝臓の炎症です。通常、長期にわたる過度のアルコール摂取が原因で生じます。症状には、食欲の変化、口渇、体重減少、皮膚・目の黄変 (黄疸) 、発熱、疲労感などが含まれます。

当レポートでは、アルコール性肝炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

アルコール性肝炎の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

アルコール性肝炎:企業で開発中の治療薬

アルコール性肝炎:大学/機関で研究中の治療薬

アルコール性肝炎:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

アルコール性肝炎:企業で開発中の製品

アルコール性肝炎:大学/機関で研究中の製品

アルコール性肝炎の治療薬開発に従事している企業

  • Alfact Innovation
  • Conatus Pharmaceuticals Inc.
  • Generon (Shanghai) Corporation Ltd.
  • Immuron Limited
  • Intercept Pharmaceuticals, Inc.
  • Promethera Biosciences S.A.
  • Verlyx Pharma Inc.
  • アルコール性肝炎:治療薬の評価
  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

アルコール性肝炎:最近のパイプライン動向

アルコール性肝炎:休止中のプロジェクト

アルコール性肝炎:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8461IDB

Summary

Global Markets Direct's, 'Alcoholic Hepatitis - Pipeline Review, H2 2016', provides an overview of the Alcoholic Hepatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis
  • The report reviews pipeline therapeutics for Alcoholic Hepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Alcoholic Hepatitis therapeutics and enlists all their major and minor projects
  • The report assesses Alcoholic Hepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Alcoholic Hepatitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alcoholic Hepatitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Alcoholic Hepatitis Overview
  • Therapeutics Development
    • Pipeline Products for Alcoholic Hepatitis - Overview
    • Pipeline Products for Alcoholic Hepatitis - Comparative Analysis
  • Alcoholic Hepatitis - Therapeutics under Development by Companies
  • Alcoholic Hepatitis - Therapeutics under Investigation by Universities/Institutes
  • Alcoholic Hepatitis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Alcoholic Hepatitis - Products under Development by Companies
  • Alcoholic Hepatitis - Products under Investigation by Universities/Institutes
  • Alcoholic Hepatitis - Companies Involved in Therapeutics Development
    • Alfact Innovation
    • Conatus Pharmaceuticals Inc.
    • Generon (Shanghai) Corporation Ltd.
    • Genextra S.p.a.
    • Gilead Sciences, Inc.
    • GRI Bio, Inc.
    • Immuron Limited
    • Promethera Biosciences S.A.
    • Verlyx Pharma Inc.
  • Alcoholic Hepatitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALF-5755 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emricasan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • F-652 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRI-0621 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HepaStem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMM-124E - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • obeticholic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pentamidine isethionate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMKM-02GI1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selonsertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Alcoholic Hepatitis - Dormant Projects
  • Alcoholic Hepatitis - Product Development Milestones
    • Featured News & Press Releases
      • Sep 11, 2013: Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver Failure Patients
      • Sep 10, 2013: Conatus Pharmaceuticals' Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Alcoholic Hepatitis, H2 2016
  • Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Alcoholic Hepatitis - Pipeline by Alfact Innovation, H2 2016
  • Alcoholic Hepatitis - Pipeline by Conatus Pharmaceuticals Inc., H2 2016
  • Alcoholic Hepatitis - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016
  • Alcoholic Hepatitis - Pipeline by Genextra S.p.a., H2 2016
  • Alcoholic Hepatitis - Pipeline by Gilead Sciences, Inc., H2 2016
  • Alcoholic Hepatitis - Pipeline by GRI Bio, Inc., H2 2016
  • Alcoholic Hepatitis - Pipeline by Immuron Limited, H2 2016
  • Alcoholic Hepatitis - Pipeline by Promethera Biosciences S.A., H2 2016
  • Alcoholic Hepatitis - Pipeline by Verlyx Pharma Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Alcoholic Hepatitis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Alcoholic Hepatitis, H2 2016
  • Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top